Entero Healthcare Solutions Limited has submitted its Unaudited Consolidated and Standalone Financial Results for the quarter and nine months ended December 31, 2025. The filing, dated February 13, 2026, confirms the generation of necessary UDINs for the financial data. Key updates include provisional accounting for recent acquisitions and the recognition of an exceptional item related to the new Labour Codes impacting employee benefit obligations.
Official Submission of Q3 FY2025-26 Results
Entero Healthcare Solutions Limited has formally submitted its Unaudited Standalone and Consolidated Financial Results for the third quarter and the nine months ended December 31, 2025, to the stock exchanges. This submission followed an earlier communication dated February 12, 2026, and includes the requisite UDINs generated by the Statutory Auditors.
Key Standalone Financial Highlights (Q3 Ended Dec 31, 2025)
For the quarter ended December 31, 2025 (Unaudited Standalone basis):
- Total Income: Stood at Rs. 1,299.90 Million.
- Profit Before Tax: Reported at Rs. 13.74 Million.
- Profit After Tax (PAT): Amounted to Rs. 8.05 Million.
- Earnings Per Share (Diluted): Calculated at Rs. 0.18 (not annualised).
For the nine months ended December 31, 2025 (Unaudited Standalone basis):
- Total Income: Reached Rs. 3,430.76 Million.
- Profit After Tax (PAT): Totaled Rs. 134.59 Million.
Key Consolidated Financial Highlights (Q3 Ended Dec 31, 2025)
For the quarter ended December 31, 2025 (Unaudited Consolidated basis):
- Total Income: Reported at Rs. 17,111.02 Million.
- Profit Before Tax: Stood at Rs. 485.77 Million.
- Profit After Tax (PAT) including Exceptional Item: Amounted to Rs. 338.78 Million.
For the nine months ended December 31, 2025 (Unaudited Consolidated basis):
- Total Income: Reached Rs. 46,659.47 Million.
- Profit After Tax (PAT) including Exceptional Item: Totaled Rs. 1,007.12 Million.
Notes on Acquisitions and Exceptional Items
Provisional Business Combinations
The results for the current period include provisional figures from several acquisitions made during the period ended December 31, 2025, including Ramson Medical Distributors, Sai RK Pharma, and Ace Cardiopathy Solutions, among others. Subsequent to the period, Anand Chemiceutics Private Limited was also acquired on February 7, 2026.
Exceptional Item Adjustment (Consolidated)
An Exceptional Item of Rs. 81.78 Million (Net of tax: Rs. 61.14 Million) was recognized on a consolidated basis due to the reassessment of employee benefit obligations following the introduction of the New Labour Codes effective November 21, 2025.
Subsidiary Status Changes
The company noted the striking off of three non-operating subsidiaries (Zennx, Quromed, and Rimedio) during the period. Furthermore, Suprabhat Pharmaceuticals Private Limited ceased to be a subsidiary effective September 29, 2025, following the sale of the entire equity shareholding.
IPO Proceeds Utilisation
The utilization of the net IPO proceeds remains consistent across the reporting periods, totalling Rs. 9,548.00 Million utilized up to December 31, 2025, covering borrowings repayment, working capital, and inorganic growth initiatives. The portion allocated for General Corporate Purposes was adjusted slightly due to lower actual IPO expenditure than estimated.
Source: BSE
